
Opinion|Videos|August 19, 2024
Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Experts discuss future directions of BTK inhibitors.
Advertisement
Video content above is prompted by the following:
- Let’s discuss anticipated (or just presented) data from ASCO 2024 on the treatment of CLL. What data or insights are you most looking forward to coming out of ASCO 2024?
- How might emerging biomarkers influence the development and use of BTK inhibitors in CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Major Bleeding Prevention, Treatment Requires Vigilance in Patients With ET
2
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
3
Medicare Insulin Savings Model Cuts Costs, Boosts Access, Report Finds
4
Executive Order on Homelessness Includes Several Policy Shifts: Katherine Koh, MD, MSc
5